News Releases

CAMBRIDGE, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that its management team will participat...

Manuscript further details positive clinical results and long-term tolerability of mavorixafor in ongoing Phase 2 study Company continues to advance mavorixafor in Phase 3 pivotal trial in WHIM using optimal dose and key endpoints from Phase 2 trial CAMBRIDGE, Mass. , Sept....

CAMBRIDGE, Mass. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq:  XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on August 31, 2020 , the Compensa...

CAMBRIDGE, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct ...

CAMBRIDGE, Mass. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on August 4, 2020 , the Compensatio...

Presentation of positive clinical data at EHA 2020 supporting the ongoing Phase 3 trial in WHIM syndrome Initial data expected later this year from Phase 1b clinical trial in Waldenström’s macroglobulinemia Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass....

CAMBRIDGE, Mass. , July 16, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results...

CAMBRIDGE, Mass. , July 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on June 30, 2020 , the Compensation...

Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshold for absolute neutrophil count as primary endpoint Significant reductions in yearly infect...

CAMBRIDGE, Mass. , June 11, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the promotion of Renato Skerlj , Ph.D., t...

Conference call to take place on Friday, June 12, 2020, at 8:30 am ET CAMBRIDGE, Mass. , June 08, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CX...

CAMBRIDGE, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq:  XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on May 29, 2020 , the Compensation...

CAMBRIDGE, Mass. , May 28, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that its management team will present and ...

Data reveal reductions in annual infections and warts, and sustained dose-dependent increases in neutrophil counts These and additional Phase 2 data to be presented in an e-Poster on June 12 th at the Virtual Edition of the 25 th Congress of the European Hematology Association (E...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 12, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its stockholders, employees and ot...

Data from Phase 2 open-label extension trial of mavorixafor in WHIM syndrome to be presented at the Virtual Edition of the 25 th European Hematology Association (EHA) Annual Congress in June 2020 Company continues to expect data from its Phase 1b Waldenström’s macroglobulinemia t...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 23, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results ...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 9, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct on...

– Market research confirms U.S. WHIM prevalence of 1,000 – 1,300 diagnosed patients, with an additional 800 – 2,400 potential undiagnosed patients– CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 7, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and developmen...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that on March 31, 2020 , the Compensation C...